Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV Melanoma

ClinicalTrials.gov ID: NCT00039000

Public ClinicalTrials.gov record NCT00039000. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 4:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus Physician's Choice Including Interleukin-2 and/or Dacarbazine/Temozolomide-based Therapy and/or Complete Tumor Resection in Stage IV Melanoma

Study identification

NCT ID
NCT00039000
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Agenus Inc.
Industry
Enrollment
350 participants

Conditions and interventions

Interventions

  • HSPPC-96 or Oncophage Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2002
Primary completion
Nov 30, 2005
Completion
Nov 30, 2005
Last update posted
Sep 6, 2012

2002 – 2005

United States locations

U.S. sites
35
U.S. states
24
U.S. cities
35
Facility City State ZIP Site status
Not listed Birmingham Alabama
Not listed Scottsdale Arizona
Not listed Berkeley California
Not listed Los Angeles California
Not listed Stanford California
Not listed Vista California
Not listed Denver Colorado
Not listed Farmington Connecticut
Not listed Jacksonville Florida
Not listed Lakeland Florida
Not listed Miami Beach Florida
Not listed Atlanta Georgia
Not listed Chicago Illinois
Not listed Park Ridge Illinois
Not listed Kansas City Kansas
Not listed Louisville Kentucky
Not listed Baltimore Maryland
Not listed Boston Massachusetts
Not listed Robbinsdale Minnesota
Not listed Rochester Minnesota
Not listed Columbia Missouri
Not listed St Louis Missouri
Not listed Lebanon New Hampshire
Not listed New Brunswick New Jersey
Not listed New York New York
Not listed Cincinnati Ohio
Not listed Cleveland Ohio
Not listed Tulsa Oklahoma
Not listed Portland Oregon
Not listed Philadelphia Pennsylvania
Not listed Pittsburgh Pennsylvania
Not listed Knoxville Tennessee
Not listed Dallas Texas
Not listed Houston Texas
Not listed Madison Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00039000, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 6, 2012 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00039000 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →